China-based drugmakers that once fueled a surge of copycat weight-loss treatments in the U.S. are now pivoting to generics of Novo Nordisk‘s (NYSE:NVO) Wegovy and Eli Lilly's (NYSE:LLY) Zepbound as regulators tighten rules on compounded medicines.
After unprecedented demand strained branded supplies, at least eight Chinese firms—including Jiangsu Sinopep-Allsino and Hybio Pharmaceutical—supplied raw ingredients that helped produce more than a billion makeshift doses in 2024, according to FDA shipping data cited by Reuters.
